SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Aerovate Therapeutics, Inc. (Nasdaq – AVTE)

BALA CYNWYD – October 31, 2024 /Newsfile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (Nasdaq – AVTE) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Jade Biosciences (“Jade”). Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders — including those investors participating in the pre-closing financing — are expected to own approximately 98.4% of the combined entity.

The investigation concerns whether Aerovate Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Jade is paying fair value to shareholders of the Company.

If you own shares of Aerovate stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.